TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China ...

Investing.com -- TD Cowen downgraded Illumina Inc (NASDAQ:ILMN) to "Hold" following the company's fourth-quarter earnings, citing weaker-than-expected next-generation sequencing (NGS) consumable ...

Investing.com -- TD Cowen downgraded Merck & Company Inc (NYSE:MRK) to "Hold" on concerns over uncertainty surrounding Gardasil sales, a slowdown in business development, and the looming loss of ...

Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry ...

Investing.com -- TD Cowen downgraded Merck &Company Inc (NYSE:MRK) to "Hold" on concerns over uncertainty surrounding Gardasil sales, a slowdown in business development, and the looming loss of ...

today announced plans to participate in the upcoming TD Cowen 45 th Annual Health Care Conference, being held in Boston, MA.

On Tuesday, TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in the endocrine market and the high potential of its product ...

Investing.com -- TD Cowen downgraded Celsius Holdings (NASDAQ:CELH) to Hold and slashed its price target for the stock to $29 from $40 in a note Wednesday, citing slowing sales growth ...